Tavapadon as adjunct to levodopa increases daily ON time in Parkinson’s disease

For patients with Parkinson’s disease with motor fluctuations, the oral once-daily, selective D1/D5 partial dopamine agonist tavapadon as an adjunct to levodopa increases total daily ON time versus placebo, according to a study presented at the annual meeting of the American Academy of Neurology, held from April 5 to 9 in San Diego.